Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasm Metastasis 3Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Multiple Myeloma 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1Esophageal Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1Breast Neoplasms 1Blast Crisis 1Adenocarcinoma 1

Interventions

Sorafenib 20Bevacizumab 7pembrolizumab 5Oxaliplatin 5Melphalan 5Leucovorin 5Irinotecan 5Nivolumab 4Ipilimumab 4Fluorouracil 4Cyclophosphamide 4Capecitabine 4fludarabine 3Sirolimus 3Radiosurgery 3Gemcitabine 3Filgrastim 3Carboplatin 3toripalimab 2spartalizumab 2regorafenib 2pazopanib 2lenvatinib 2ixabepilone 2durvalumab 2atezolizumab 2Vorinostat 2Thiotepa 2Temozolomide 2Sirtuins 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Liver Neoplasms × STA 9090 × Clear all
NCT01665937 2018-04-25

STA-9090 in Patients With Advanced Hepatocellular Cancer

Massachusetts General Hospital

Phase 1 Completed
16 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡